ALBANY MOLECULAR RESEARCH OPENING SINGAPORE RESEARCH CENTRE

US drug development company Albany Molecular Research (AMRI) has announced the creation of a new drug discovery facility in Singapore. The company hopes the new centre will expand its contract research operations, as well as lead to new opportunities for its manufacturing capabilities. The new subsidiary will specifically target markets in Japan, Australia and the Pacific Rim.

The Singaporean government has assisted AMRI's new investment, which is likely to benefit both the local sector and the US company, as Asian drug companies increasingly out-license some research operations. Furthermore, Singapore is virtually unique in the region in that its intellectual property legislation is largely in line with Western standards.